BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Harreiter J, Just I, Leutner M, Bastian M, Brath H, Schelkshorn C, Klepochova R, Krššák M, Kautzky-Willer A. Combined exenatide and dapagliflozin has no additive effects on reduction of hepatocellular lipids despite better glycaemic control in patients with type 2 diabetes mellitus treated with metformin: EXENDA, a 24-week, prospective, randomized, placebo-controlled pilot trial. Diabetes Obes Metab 2021;23:1129-39. [PMID: 33464703 DOI: 10.1111/dom.14319] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
Number Citing Articles
1 Shi Q, Wang Y, Hao Q, Vandvik PO, Guyatt G, Li J, Chen Z, Xu S, Shen Y, Ge L, Sun F, Li L, Yu J, Nong K, Zou X, Zhu S, Wang C, Zhang S, Qiao Z, Jian Z, Li Y, Zhang X, Chen K, Qu F, Wu Y, He Y, Tian H, Li S. Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials. Lancet 2021:S0140-6736(21)01640-8. [PMID: 34895470 DOI: 10.1016/S0140-6736(21)01640-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 20.0] [Reference Citation Analysis]
2 Makri ES, Goulas A, Polyzos SA. Sodium-glucose co-transporter 2 inhibitors in nonalcoholic fatty liver disease. Eur J Pharmacol 2021;907:174272. [PMID: 34147478 DOI: 10.1016/j.ejphar.2021.174272] [Reference Citation Analysis]
3 Vosoughi K, Atieh J, Khanna L, Khoshbin K, Prokop LJ, Davitkov P, Murad MH, Camilleri M. Association of Glucagon-like Peptide 1 Analogs and Agonists Administered for Obesity with Weight Loss and Adverse Events: A Systematic Review and Network Meta-analysis. EClinicalMedicine 2021;42:101213. [PMID: 34877513 DOI: 10.1016/j.eclinm.2021.101213] [Reference Citation Analysis]
4 Koike M, Saito H, Kohno G, Takubo M, Watanabe K, Ishihara H. Effects of GLP-1RA and SGLT2i, Alone or in Combination, on Mouse Models of Type 2 Diabetes Representing Different Disease Stages. Int J Mol Sci 2021;22:11463. [PMID: 34768897 DOI: 10.3390/ijms222111463] [Reference Citation Analysis]
5 López-Cano C, Santos MD, Sánchez E, Martí R, Bueno M, Gutiérrez-Carrasquilla L, Lecube A. Dapagliflozin plus exenatide on patients with type 2 diabetes awaiting bariatric surgery in the DEXBASU study. Sci Rep 2022;12:3236. [PMID: 35217772 DOI: 10.1038/s41598-022-07250-z] [Reference Citation Analysis]
6 Kahl S, Pützer J, Roden M. Novel Antidiabetic Strategies and Diabetologists' Views in Nonalcoholic Steatohepatitis. Semin Liver Dis 2021. [PMID: 34289506 DOI: 10.1055/s-0041-1732354] [Reference Citation Analysis]
7 Brown E, Heerspink HJL, Cuthbertson DJ, Wilding JPH. SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. Lancet 2021;398:262-76. [PMID: 34216571 DOI: 10.1016/S0140-6736(21)00536-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Brown E, Hydes T, Hamid A, Cuthbertson DJ. Emerging and Established Therapeutic Approaches for Nonalcoholic Fatty Liver Disease. Clin Ther 2021;43:1476-504. [PMID: 34446271 DOI: 10.1016/j.clinthera.2021.07.013] [Reference Citation Analysis]
9 Li C, Luo J, Jiang M, Wang K. The Efficacy and Safety of the Combination Therapy With GLP-1 Receptor Agonists and SGLT-2 Inhibitors in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis. Front Pharmacol 2022;13:838277. [DOI: 10.3389/fphar.2022.838277] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
10 Harreiter J, Just I, Leutner M, Bastian M, Brath H, Schelkshorn C, Klepochova R, Krššák M, Kautzky-Willer A. Combined exenatide and dapagliflozin has no additive effects on reduction of hepatocellular lipids despite better glycaemic control in patients with type 2 diabetes mellitus treated with metformin: EXENDA, a 24-week, prospective, randomized, placebo-controlled pilot trial. Diabetes Obes Metab 2021;23:1129-39. [PMID: 33464703 DOI: 10.1111/dom.14319] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]